These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 22970327)
1. Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. Kim YW; Bae SM; Lim H; Kim YJ; Ahn WS PLoS One; 2012; 7(9):e44960. PubMed ID: 22970327 [TBL] [Abstract][Full Text] [Related]
2. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer. Kim YW; Bae SM; Kim IW; Liu HB; Bang HJ; Chaturvedi PK; Battogtokh G; Lim H; Ahn WS Oncol Rep; 2012 Aug; 28(2):585-91. PubMed ID: 22641176 [TBL] [Abstract][Full Text] [Related]
3. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402 [TBL] [Abstract][Full Text] [Related]
4. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095 [TBL] [Abstract][Full Text] [Related]
5. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tcherkassova J; Abramovich C; Moro R; Chen C; Schmit R; Gerber A; Moro R Tumour Biol; 2011 Aug; 32(4):831-8. PubMed ID: 21625941 [TBL] [Abstract][Full Text] [Related]
6. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390 [TBL] [Abstract][Full Text] [Related]
7. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Zhang Z; Bast RC; Yu Y; Li J; Sokoll LJ; Rai AJ; Rosenzweig JM; Cameron B; Wang YY; Meng XY; Berchuck A; Van Haaften-Day C; Hacker NF; de Bruijn HW; van der Zee AG; Jacobs IJ; Fung ET; Chan DW Cancer Res; 2004 Aug; 64(16):5882-90. PubMed ID: 15313933 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570 [TBL] [Abstract][Full Text] [Related]
9. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593 [TBL] [Abstract][Full Text] [Related]
10. CA125 and HE4: Measurement Tools for Ovarian Cancer. Zhao T; Hu W Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726 [TBL] [Abstract][Full Text] [Related]
11. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of serum mesothelin in malignant and benign ovarian masses. Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964 [TBL] [Abstract][Full Text] [Related]
13. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475 [TBL] [Abstract][Full Text] [Related]
14. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Shadfan BH; Simmons AR; Simmons GW; Ho A; Wong J; Lu KH; Bast RC; McDevitt JT Cancer Prev Res (Phila); 2015 Jan; 8(1):37-48. PubMed ID: 25388014 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay. Horala A; Swiatly A; Matysiak J; Banach P; Nowak-Markwitz E; Kokot ZJ Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075407 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Moore LE; Fung ET; McGuire M; Rabkin CC; Molinaro A; Wang Z; Zhang F; Wang J; Yip C; Meng XY; Pfeiffer RM Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1641-6. PubMed ID: 16985025 [TBL] [Abstract][Full Text] [Related]
18. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066 [TBL] [Abstract][Full Text] [Related]
19. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595 [TBL] [Abstract][Full Text] [Related]
20. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer. Xi QP; Pu DH; Lu WN Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]